SUMMARY Twenty-four-hour ambulatory blood pressure, including the acceleration phase, and left ventricular mass were evaluated in 16 patients with isolated systolic hypertension (standing blood pressure >160 mm Hg systolic and s 9 5 mm Hg diastolic). After a 4-week, single-blind, placebo period, each patient underwent 24-hour ambulatory blood pressure monitoring and echocardiography. Labetalol therapy was then initiated at 100 mg twice a day in a single-blind manner and increased weekly by 100 mg twice a day until blood pressure control was obtained or a maximum dosage of 400 mg twice a day was reached. Blood pressure control was achieved at a mean daily dose of 363 ± 46 mg of labetalol. Measurements were repeated at the end of an 8-week maintenance phase. Labetalol therapy significantly reduced the mean 24-hour systolic ambulatory blood pressure from 154 ± 8 (mean ± SEM) mm Hg at baseline to 142 ± 6 mm Hg (p > 0.01) and controlled the early morning surge in systolic ambulatory blood pressure. Minor reductions in diastolic blood pressure and heart rate were statistically but not clinically significant. Left ventricular mass was not changed. Labetalol monotherapy provides effective 24-hour control of systolic blood pressure, including the acceleration phase, in patients with isolated systolic hypertension. (Hypertension 11 [Suppl I]: I-198-I-201,1988) KEY WORDS • ambulatory blood pressure • left ventricular mass • antihypertensive therapy I SOLATED systolic hypertension, usually defined as systolic blood pressure (BP) of 160 mm Hg or higher with a diastolic BP of 90 mm Hg or below, occurs in approximately 5% of the hypertensive population. Although it can occur in young and middleaged patients, its prevalence increases dramatically with age.
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SOLATED systolic hypertension, usually defined as systolic blood pressure (BP) of 160 mm Hg or higher with a diastolic BP of 90 mm Hg or below, occurs in approximately 5% of the hypertensive population. Although it can occur in young and middleaged patients, its prevalence increases dramatically with age. 1 The Framingham Study and others concluded that isolated systolic hypertension increases the risk of stroke and cardiovascular morbidity and mortality by at least twofold. '"* Of particular importance in patients with isolated systolic hypertension may be the need to control surges in heart rate and BP, particularly the rapid rise that commences just before awakening and continues until midday. 3 The observation that stroke,' sudden death, 7 and myocardial infarction 8 occur more frequently during the morning suggests that this surge in BP may have sinister consequences. /3-receptor blockers without a-blockade have not proved to be effective in lowering BP during this period, 9 and it has been suggested that this rapid acceleration of BP may be the result of intense sympathetic activity mediated by a-receptors. 3 Labetalol is an antihypertensive agent that acts by reducing peripheral vascular resistance through a,-adrenergic blockade and preventing reflex tachycardia and hyperreninemia through /3-blockade. 10 This combination of a,-and /3-adrenergic blockade could contribute to improved control of morning surges in BP.
The objectives of the current study in patients with isolated systolic hypertension were to assess the nature of BP acceleration, the efficacy of labetalol in blunting this surge, 24-hour ambulatory BP control, and left ventricular (LV) mass.
Subjects and Methods
Male and female volunteers with suspected isolated systolic hypertension were enrolled into the placebo phase of the study. Patients with serious disease, secondary hypertension, standing systolic BP of 250 mm Hg or above, or contraindications to /3-blockers were excluded from enrollment.
The trial consisted of three phases: a 4-week placebo washout period, a single-blind labetalol titration period lasting up to 4 weeks, and an 8-week maintenance period. At the initial visit, patients were instructed to discontinue all antihypertensive therapy and were given placebo to take twice daily for 4 weeks in a LABETALOL FOR ISOLATED SYSTOUC HYPERTENSION/Deei«»fro et al. single-blind fashion. At the end of this 4-week period, only patients with a standing systolic BP of 160 mm Hg or above and a standing diastolic BP of 95 mm Hg or below were eligible for the labetalol titration phase. At this point, while taking placebo, each patient underwent 24-hour ambulatory BP monitoring and M-mode and two-dimensional echocardiography. During the titration phase, the initial dosage of labetalol was 100 mg twice a day. Dosage was adjusted weekly in increments of 100 mg twice a day until 1) BP control was achieved, 2) a maximum dosage of 400 mg twice a day was taken for 1 week without BP control, or 3) an intolerable side effect developed. BP control was defined according to the baseline standing systolic BP, taken at the end of the placebo phase. BP was considered controlled if standing BP was reduced to below 160 mm Hg or was reduced 10% or more for patients whose baseline BP was above 180 mm Hg. If BP control was achieved during the titration period, patients continued in the study for an additional 8 weeks of maintenance therapy. At the end of this time, while taking active medication, each patient underwent a second 24-hour ambulatory BP monitoring and echocardiographic evaluation. BP, heart rate, body weight, and adverse events were recorded at each visit throughout the study.
Ambulatory BP was monitored with an ICR 5200 monitor (Spacelabs, Bellevue, WA, USA). The monitor was adapted to take one reading every 15 minutes over each 24-hour period. At least 70% of both the placebo and the maintenance recordings had to be evaluable for the patient to be included in the analysis. Each patient was also required to record daily activities on a diary card.
The mean values for systolic and diastolic BP and heart rate were plotted on a 24-hour axis to obtain circadian curves, and the points making up these curves were then compared before and after treatment. To standardize the activity-inactivity cycle of each patient, the time of awakening was carefully recorded, and these curves were normalized around this time for comparison of BP changes. An ultrasound system (600 series, Advanced Technology Laboratory, Seattle, WA, USA) was used for echocardiography. Measurements were made in the left lateral decubitus position on three complexes. Septal wall thickness, posterior wall thickness, and LV dimension were measured by M-mode echocardiography. The probe was guided to identify the exact part of the ventricle. A hard-copy photograph was made to reproduce the beam angle for subsequent measurements. Leading edge techniques as recommended by the American Society of Echocardiography and mass measurement as proposed by Reichek and Devereaux" were used.
The research protocol was approved by the institutional review board. Informed consent was obtained from participants before they entered the study.
Results
Twenty-two patients entered the drug phase of the trial; the BP of one patient was uncontrolled with labetalol, 400 mg twice a day during titration, and the patient was discontinued. Two patients completed the study but did not have both 24-hour ambulatory readings performed due to mechanical difficulties. One patient withdrew from the study for personal reasons, one withdrew due to an adverse event (i.e., diarrhea), and one was lost to follow-up. Ten men and 6 women completed the trial. The mean (± SEM) age was 61 ± 2 years; weight was 86.8 ± 3.6 kg; baseline BP was 170 ± ll/83±5mmHg.
The pretreatment 24-hour BP and heart rate curves demonstrate a circadian pattern similar to that reported previously. 3 The highest recordings occurred between 0800 and 1200. Both values then slowly declined over the afternoon and early evening, until the lowest levels were reached during the sleeping hours.
During the early morning acceleration period, defined as the segment of time from 0400 to 1200 when BP and heart rate rise most rapidly, labetalol lowered systolic BP. The effectiveness of labetalol in controlling this early morning rise is best illustrated when the data are adjusted for the time of awakening (Figure 1) . Time zero was designated as the time at which each patient awakened. Systolic BP at time zero decreased from 157 ± 12 mm Hg at baseline to 144 ± 11 mm Hg (p<0.0l). Figure 1 shows that systolic BP began to rise 2 to 3 hours prior to awakening and steadily increased for the first 5 hours after the patients had arisen. During this 7-hour time span in the placebo phase, the hourly mean systolic BP exceeded 160 mm Hg in five of the seven hourly periods. With labetalol treatment, however, systolic BP was lower during each of these hourly periods (p<0.05). A similar effect was observed on heart rate. Diastolic BP changed little during both placebo and labetalol periods. Also, labetalol had little effect on BP or heart rate during the sleeping hours. Furthermore, the drug lowered mean 24-hour systolic BP (154 ± 8 vs 142 ± 6 mm Hg; p< 0.01) and the number of BP recordings exceeding 160 mm Hg (38 vs 21; p<0.02). Reductions in diastolic BP and heart rate were minor (Table 1) . After labetalol therapy, LV mass was not changed. Labetalol effectively maintained control of the systolic BP in all 16 patients during the 8-week maintenance period. The average dosage required for control was approximately 200 mg twice a day (363 ± 46 mg/day).
The drug was well tolerated. One patient was dropped due to persistent diarrhea, thought to be associated with labetalol. Three others reported side effects considered to be drug-related (nausea and vomiting, bad taste and dry mouth, transient dizziness), but these were not sufficient to warrant stopping the medication.
Discussion
Isolated systolic hypertension occurs predominantly in the elderly population' 12 and is associated with an increased risk of stroke and cardiovascular morbidity and mortality. '^ Although the benefits of treatment are yet unknown, it seems reasonable that therapy should control systolic BP throughout the day, especially during the arousal and early moring period, since it is during this time that the occurrence of stroke, sudden death, and myocardial infarction is highest relative to other times of day. 6 "* Labetalol significantly reduced the mean 24-hour systolic BP in a group of 16 patients with isolated systolic hypertension, with only a minor effect on diastolic BP. When the 24-hour data are adjusted for time of awakening, it is clear that labetalol controlled the surges in systolic BP and heart rate during the arousal and early morning period. While this was reported previously with labetalol in patients with diastolic hypertension, 1213 conventional /3-blockers were not effective during this critical period. 9 The a-blocking properties of labetalol may account for this difference.
Regression of LV hypertrophy has been reported after therapy with antihypertensive agents, such as sympatholytics and converting enzyme inhibitors, but has not been observed with some vasodilators or diuretics despite adequate BP control.
14 However, regression of hypertrophy did not occur in all patients, even with the effective drugs." There was weak or no correlation between BP response and reduction in LV mass in these studies, 13 suggesting that factors in addition to BP control are involved in the reduction of LV mass by antihypertensive therapy. Results of initial studies of the effectiveness of /3-blockers in regressing hypertrophy were controversial, but evidence is accumulating that these drugs are indeed effective in reducing LV mass, probably with prolonged (^ 8 mo) therapy. 16 An earlier study found that labetalol reduced septal wall thickness in primary hypertension, 17 but there have been no previous reports on isolated systolic hypertension. That condition is characterized by poor compliance of large vessels, and the features of hypertrophy of the ventricle may be different from those in diastolic hypertension. Thus, the lack of reduction of LV mass associated with BP control in these 16 patients after labetalol therapy may be related to both the nature of the hypertrophy and the relatively short period of therapy (8 weeks).
In conclusion, labetalol effectively and safely controlled systolic BP throughout the day in patients with isolated systolic hypertension. This included controlling the surges in BP and heart rate that are usually part of early morning arousal and those related to day-to-day activities. Labetalol should be considered as a reasonable choice for monotherapy of patients with isolated systolic hypertension.
